Patents by Inventor Babal Kant Jha

Babal Kant Jha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230331663
    Abstract: Compounds that can be used to increase NAD levels are described by inhibiting NAD+ degrading enzymes such as CD38 are described. The compounds have a structure according to formula I or Formula II, as described herein, or pharmaceutically acceptable salts thereof, wherein the attached groups are as defined in the specification. Methods of increasing intracellular NAD+ levels in a subject by administering an effective amount of a compound according to formula I or formula II to the subject are also described.
    Type: Application
    Filed: October 18, 2021
    Publication date: October 19, 2023
    Inventors: Babal Kant Jha, James G. Phillips, Jaroslaw P. Maciejewski, Frederic Joel Reu
  • Patent number: 10370373
    Abstract: Imidazopyridine derivatives according to formula I are described wherein X is selected from CH, N, S, and O, Y is selected from S, CO, and O, R1 and optional R2 are independently selected from H, OH, substituted or unsubstituted C1-C6 alkyl, and substituted or unsubstituted C4-C6 cycloalkyl or cycloheteroalkyl, R3 is selected from H, OH, substituted or unsubstituted C1-C6 alkyl, and optional Z is selected from OH, NH2, NH(CO)R4, NH(SO2)R4, guanidine, alkylguanidine, and fluoroguanidine, R4 is polyethylene glycol or substituted or unsubstituted C1-C6 alkyl, and pharmaceutically acceptable salt thereof. The imidazopyridine derivatives can be used for treatment of cancer in a subject.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: August 6, 2019
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventors: Yogenthiran Saunthararajah, Kwok Peng Ng, James G. Phillips, Babal Kant Jha, Anand Dev Tiwari
  • Publication number: 20180194764
    Abstract: Imidazopyridine derivatives according to formula I are described wherein X is selected from CH, N, S, and O, Y is selected from S, CO, and O, R1 and optional R2 are independently selected from H, OH, substituted or unsubstituted C1-C6 alkyl, and substituted or unsubstituted C4-C6 cycloalkyl or cycloheteroalkyl, R3 is selected from H, OH, substituted or unsubstituted C1-C6 alkyl, and optional Z is selected from OH, NH2, NH(CO)R4, NH(SO2)R4, guanidine, alkylguanidine, and fluoroguanidine, R4 is polyethylene glycol or substituted or unsubstituted C1-C6 alkyl, and pharmaceutically acceptable salt thereof. The imidazopyridine derivatives can be used for treatment of cancer in a subject.
    Type: Application
    Filed: March 8, 2018
    Publication date: July 12, 2018
    Inventors: Yogenthiran Saunthararajah, Kwok Peng Ng, James G. Phillips, Babal Kant Jha, Anand Dev Tiwari
  • Patent number: 9926316
    Abstract: Imidazopyridine derivatives according to formula I are described wherein X is selected from CH, N, S, and O, Y is selected from S, CO, and O, R1 and optional R2 are independently selected from H, OH, substituted or unsubstituted C1-C6 alkyl, and substituted or unsubstituted C4-C6 cycloalkyl or cycloheteroalkyl, R3 is selected from H, OH, substituted or unsubstituted C1-C6 alkyl, and optional Z is selected from OH, NH2, NH(CO)R4, NH(SO2)R4, guanidine, alkylguanidine, and fluoroguanidine, R4 is polyethylene glycol or substituted or unsubstituted C1-C6 alkyl, and pharmaceutically acceptable salt thereof. The imidazopyridine derivatives can be used for treatment of cancer in a subject.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: March 27, 2018
    Assignee: The Cleveland Clinic Foundation
    Inventors: Yogenthiran Saunthararajah, Kwok Peng Ng, James G. Phillips, Babal Kant Jha, Anand Dev Tiwari
  • Publication number: 20170057910
    Abstract: Naphthalenyl benzamide derivatives according to formula I are described, wherein Ar is an aryl or heteroaryl group, and R1-R4 are independently selected from H, halogen, CF3, hydroxyl, C1-C4 alkyl, and C1-C4 oxyalkyl, or a pharmaceutically acceptable salt thereof. The naphthalenyl benzamide derivatives can be used for the treatment of cancer in a subject.
    Type: Application
    Filed: August 29, 2016
    Publication date: March 2, 2017
    Inventors: Frederic J. Reu, Sergei Vatolin, James G. Phillips, Dale Grabowski, Babal Kant Jha
  • Publication number: 20130071432
    Abstract: One aspect of the present disclosure relates to a method for treating a subject with cancer. The method includes administering an oncolytic virus simultaneously, sequentially, or separately in combination with an immunomodulatory agent in an amount effective to suppress both antiviral immunity and angiogenesis associated with the cancer.
    Type: Application
    Filed: September 18, 2012
    Publication date: March 21, 2013
    Applicant: THE CLEVELAND CLINIC FOUNDATION
    Inventors: Robert Silverman, Babal Kant Jha